AstraZeneca PLC

AZN

GB0009895292

Pharmaceuticals

Market Closed - London S.E. Other stock markets 11:35:15 2024-06-26 EDT			5-day change	1st Jan Change
12,556 ^GBX	+0.05%		+1.75%	+18.45%

06:29pm	European Equities Close Lower in Wednesday Trading	MT
01:57pm	ASTRAZENECA : Deutsche Bank sticks Neutral	ZD

ASTRAZENECA : Goldman Sachs maintains a Buy rating

June 18, 2024 at 07:20 am

Analyst Rajan Sharma from Goldman Sachs research considers the stock attractive and recommends it with a Buy rating. The target price is unchanged at GBX 15200.

Latest news about AstraZeneca PLC

European Equities Close Lower in Wednesday Trading	12:29pm	MT
ASTRAZENECA : Deutsche Bank sticks Neutral	07:57am	ZD
AstraZeneca Says Tagrisso With Chemotherapy Approved in China	07:21am	MT
AstraZeneca: Tagrisso approved in China for NSCLC	04:03am	CF
AstraZeneca's Tagrisso plus chemo gets approval in China	03:42am	AN
China approves AstraZeneca's Tagrisso-chemo combo as first-line treatment	03:04am	RE
AstraZeneca Wins Chinese Regulatory Nod for Lung Cancer Combination Treatment	02:31am	MT
European Equities Close Lower in Tuesday Trading; EC Accuses Microsoft of Breaking Antitrust Laws	06-25	MT
European Equities Traded in the US as American Depositary Receipts Nudge Higher Tuesday Trading	06-25	MT
Global markets live: UBS, Boeing, AT&T, Rivian, Nvidia, Tesla...	06-25
AstraZeneca Says Imfinzi With Chemotherapy Improves Survival in Phase 3 Bladder Cancer Trial	06-25	MT
AstraZeneca's Tagrisso Approved With Chemotherapy in Japan for Lung Cancer Treatment	06-25	MT
AstraZeneca Says Phase 3 Imfinzi Trial in Early-Stage Lung Cancer Misses Primary Endpoint	06-25	MT
AstraZeneca Logs Hit and Miss in Oncology Drugs Portfolio	06-25	MT
AstraZeneca PLC Announces IMFINZI Demonstrates Statically Significant and Clinically Meaningful Improvement in Event-Free Survival and Overall Survival for Muscle-Invasive Bladder Cancer in Niagara Phase III Trial	06-25	CI
AstraZeneca's Imfinzi fails in late-stage trial to treat certain lung cancers	06-25	RE
ASTRAZENECA : Goldman Sachs reiterates its Buy rating	06-25	ZD
AstraZeneca: inconclusive trial for Infinzi in NSCL	06-25	CF
AstraZeneca: Tagrisso protocol approved in Japan	06-25	CF
AstraZeneca: inconclusive trial for Infinzei in NSCL	06-25	CF
AstraZeneca: conclusive trial in bladder cancer	06-25	CF
AstraZeneca details mixed findings from cancer drug trials	06-25	AN
Correction: AstraZeneca's Tagrisso Combo Wins Approval as First-line Lung Cancer Treatment in Japan	06-25	MT
AstraZeneca's Tagrisso Combo Wins Approval as First-line Lung Cancer Treatment in Japan	06-25	MT
AstraZeneca's Adjuvant Lung Cancer Drug Fails to Improve Disease-free Survival in Late-stage Trial	06-25	MT

AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (4.4%). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).

Sector

Pharmaceuticals

Calendar

2024-07-25 - Q2 2024 Earnings Release

Related indices

STOXX EUROPE 600 (EUR) , FTSE 100

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

ASTRAZENECA : Strong Q1 raises hopes of a guidance upgrade

April 25, 2024 at 12:02 pm

More Strategies

Ratings for AstraZeneca PLC

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

159 USD

Average target price

174.4 USD

Spread / Average Target

+9.66%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ASTRAZENECA PLC	+18.45%	247B
ELI LILLY AND COMPANY	+54.14%	815B
NOVO NORDISK A/S	+44.25%	654B
JOHNSON & JOHNSON	-6.32%	354B
MERCK & CO., INC.	+21.61%	337B
ABBVIE INC.	+10.84%	302B
ROCHE HOLDING AG	+2.09%	229B
NOVARTIS AG	+13.03%	219B
AMGEN INC.	+8.90%	171B
PFIZER, INC.	-4.71%	159B

Other Pharmaceuticals

AstraZeneca PLC

Equities

AZN

GB0009895292

Pharmaceuticals

ASTRAZENECA : Goldman Sachs maintains a Buy rating

Latest news about AstraZeneca PLC

Chart AstraZeneca PLC

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for AstraZeneca PLC

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals